SAN DIEGO, April 21, 2015 /PRNewswire-USNewswire/ -- The Association for Frontotemporal Degeneration (AFTD) will hold its 2015 Education Conference at the DoubleTree Hotel in Mission Valley, California on Friday, April 24, 2015. The conference will run from 9:30 a.m. to 5:30 p.m., followed by a reception.
Attendees will learn from and engage experts in FTD research and clinical care, non-pharmacological interventions and hospice. A morning session for persons diagnosed will allow informal sharing and offer an introduction to mindfulness and wellness techniques.
Registration is available online at www.theaftd.org/newsroom/aftd-2015-education-conference. The general registration fee is $75, but individuals and families can request that this fee be waived. Generous support from the conference's Platinum Sponsor, FORUM Pharmaceuticals, has helped to make that possible. Registration for health professionals is $150.
The Keynote Address will be provided by Dan Browning, a journalist covering health care and medical research for the Minneapolis-based Star Tribune. Dan published a 16-part blog series (www.nextavenue.org/expert/dan-browning) dedicated to his wife, Liz Cummings Browning, who was diagnosed with FTD and ALS and passed away in May 2014.
The keynote address is sponsored through a personal gift from Ken Fousel of San Diego, as a tribute to honor his life partner, Lynne C. Sanders, who died from the primary progressive aphasia variant of FTD on October 13, 2013. San Diego-based FTD experts contributing to the conference will include lead staff for the UCSD Alzheimer's Disease Research Center and UCSD Movement Disorders Center.
About Frontotemporal Degeneration (FTD): FTD is the most prevalent form of dementia for individuals under 60 in the U.S; roughly 60% of cases occur in people 45-64 years old. The hallmark of FTD is a gradual, progressive decline in behavior and/or language, with memory usually relatively preserved. While there are currently no treatments to slow or stop its progression, research is expanding, and we anticipate that the result will be a growing number of potential therapeutics entering clinical testing within the next few years.
About AFTD: The Association for Frontotemporal Degeneration envisions a world where FTD is understood, effectively diagnosed, treated, cured and ultimately prevented. For more information about AFTD or frontotemporal degeneration, visit www.theaftd.org or connect via www.facebook.com/TheAFTD or twitter.com/AFTDCure.